4 results on '"Jennifer Sanwogou"'
Search Results
2. Zero-dose children in Latin America: analysis of the problem and possible solutions [version 1; peer review: awaiting peer review]
- Author
-
Maria L. Avila-Aguero, Helena Brenes-Chacon, Mario Melgar, Francisco Becerra-Posada, Enrique Chacon-Cruz, Angela Gentile, Martha Ospina, Nancy Sandoval, Jennifer Sanwogou, Analia Urena, Maria T. Valenzuela, and Ana Morice
- Subjects
Opinion Article ,Articles ,dose-zero children ,DTP1 ,immunization ,vaccination ,National Immunization Technical Advisory Groups ,NITAGs - Abstract
Introduction Zero-dose children (ZDC) are defined as those that have never been reached by routine immunization services. In Latin America, almost 2.7 million infants younger than 1 year of age, have incomplete vaccination schedules, and vaccine preventable diseases such as measles or polio have increase worldwide. ZDC are reported to reside in high risk and fragile settings, including remote-rural areas, urban slums, and conflict-affected areas. Identifying the problem and settings in each country is mandatory to propose possible solutions to the immunization coverage situation. Areas covered In November 2023, a group of experts of the Latin America Society of Pediatric Infectious Diseases (SLIPE) analyzed the global and regional reality of ZDC, and present in this document an updated reality of the Latin American region and the weight of the possible interventions to overcome this problem. Expert commentary Communication is a key element to improve vaccination coverage, as it is quality and use of vaccination data. Campaigns that deliver targeted and effective messages to communities and families, provide education about vaccination, avoid missed vaccination opportunities, and coordinate efforts across different sectors and communities, among other strategies, could improve the current immunization situation.
- Published
- 2024
- Full Text
- View/download PDF
3. Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008–16: findings from the Global Rotavirus Surveillance Network
- Author
-
Negar Aliabadi, MD, Sébastien Antoni, MPH, Jason M Mwenda, PhD, Goitom Weldegebriel, MD, Joseph N M Biey, MD, Dah Cheikh, MD, Kamal Fahmy, MD, Nadia Teleb, MD, Hossam Abdelrahman Ashmony, BSc, Hinda Ahmed, PhD, Danni S Daniels, MS, Dovile Videbaek, MD, Annemarie Wasley, ScD, Simarjit Singh, MSc(IT), Lucia Helena de Oliveira, PhD, Gloria Rey-Benito, MSc, N Jennifer Sanwogou, MPH, Pushpa Ranjan Wijesinghe, MD, Jayantha B L Liyanage, MD, Batmunkh Nyambat, MD, Varja Grabovac, MSc, James D Heffelfinger, MD, Kimberley Fox, MD, Fem Julia Paladin, PhD, Tomoka Nakamura, MSPH, Mary Agócs, MD, Jillian Murray, MSPH, Thomas Cherian, MD, Catherine Yen, MD, Umesh D Parashar, MBBS, Fatima Serhan, PhD, Jacqueline E Tate, PhD, and Adam L Cohen, MD
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Summary: Background: Rotavirus vaccine use in national immunisation programmes has led to declines in hospital admissions for rotavirus gastroenteritis among children; however, the global impact of rotavirus vaccine introduction has not been described using primary data. We describe the impact of rotavirus vaccine introduction on admissions for acute rotavirus gastroenteritis in primarily low-income and middle-income countries, using 9 years of data from the WHO-coordinated Global Rotavirus Surveillance Network (GRSN). Methods: Between Jan 1, 2008, and Dec 31, 2016, children younger than 5 years of age who were admitted to hospital with acute gastroenteritis were prospectively enrolled in GRSN sites. We included sites that enrolled children and collected stool specimens monthly and tested at least 100 specimens annually in the impact analysis, with a separate analysis taking into account site continuity. We compared proportions of acute gastroenteritis cases positive for rotavirus in the pre-vaccine and post-vaccine periods and calculated mean proportion changes for WHO regions, with 95% CIs; these findings were then compared with interrupted time series analyses. We did further sensitivity analyses to account for rotavirus vaccination coverage levels and sites that collected specimens for at least 11 months per year and tested at least 80 specimens per year. We also analysed the age distribution of rotavirus-positive cases before and after vaccine introduction. Findings: 403 140 children younger than 5 years of age admitted to hospital with acute gastroenteritis from 349 sites in 82 countries were enrolled over the study period, of whom 132 736 (32·9%) were positive for rotavirus. We included 305 789 children from 198 sites in 69 countries in the impact analysis. In countries that had not introduced rotavirus vaccine in their national immunisation programmes, rotavirus was detected in 38·0% (95% CI 4·8–73·4) of admissions for acute gastroenteritis annually whereas in those that have introduced the vaccine, rotavirus was detected in 23·0% (0·7–57·7) of admissions for acute gastroenteritis, showing a 39·6% (35·4–43·8) relative decline following introduction. Interrupted time series analyses confirmed these findings. Reductions by WHO regions ranged from 26·4% (15·0–37·8) in the Eastern Mediterranean Region to 55·2% (43·0–67·4) in the European Region and were sustained in nine countries (contributing up to 31 sites) for 6–10 years. The age distribution of children with rotavirus gastroenteritis shifted towards older children after rotavirus vaccine introduction. Interpretation: A significant and sustained reduction in the proportion of hospital admissions for acute gastroenteritis due to rotavirus was seen among children younger than 5 years in GRSN sites following rotavirus vaccine introduction. These findings highlight the need to incorporate rotavirus vaccines into immunisation programmes in countries that have not yet introduced them and underline the importance of high-quality surveillance. Funding: The GRSN receives funding from Gavi, the Vaccine Alliance and the US Centers for Disease Control and Prevention. No specific funding was provided for this Article.
- Published
- 2019
- Full Text
- View/download PDF
4. Establishing priorities to strengthen National Immunization Technical Advisory Groups in Latin America and the Caribbean.
- Author
-
Evans-Gilbert, Tracy, Figueroa, J. Peter, Bonvehí, Pablo, Melgar, Mario, Stecher, Daniel, Kfouri, Renato, Munoz, Greta, Bansie, Rakesh, Valenzuela, Renato, Verne, Eduardo, Salas, Daniel, and Jennifer Sanwogou, N.
- Subjects
- *
NATIONAL interest , *IMMUNIZATION , *VACCINATION coverage , *VACCINE hesitancy , *STANDARD operating procedure - Abstract
• Lack of expertise, integrating policy recommendations, and visibility were challenges. • Collaboration, linkages to policymakers, and effective communication were opportunities. • Optimizing the Regional NITAG Network is one of the most promising ways forward. Following the COVID-19 pandemic, the Americas faced a significant decline in vaccination coverage as well as increased vaccine hesitancy. The objective of this paper is to summarize the challenges and opportunities outlined by the National Immunization Technical Advisory Groups (NITAGs) in Latin America and the Caribbean (LAC) and prioritize targeted interventions. The exploratory survey included open-ended questions on two primary components: challenges, and opportunities. Free-text comments presented by each NITAG were collated and classified using indicators and sub-indicators of the NITAG Maturity Assessment Tool (NMAT). Opportunities were classified thematically, and priority actions were generated from the responses. All 21 NITAGs in LAC, representing 40 countries, 76 % of which have been active for over a decade, responded to the survey. The most common challenges were establishment and composition (62 %), integration into policymaking (62 %), resources and secretariat (52 %), and stakeholder recognition (48 %). The distribution of responses was seen across the whole sample and did not suggest a more pronounced need in relation to year of establishment. Opportunities included maximizing the Regional NITAG Network of the Americas (RNA) to facilitate collaboration, information sharing, visibility, and communication; existing global, regional, and systemic analyses; the World Health Organization/Pan American Health Organization (WHO/PAHO) templates for standard operating procedures; twinning programs with mature NITAGs; and NITAGs in governance structures. Action plans were outlined to formalize the establishment of NITAGs and broaden their composition; strengthen decision-making and access to data resources; and enhance the credibility of evidence-based recommendations and their uptake by policymakers and the public. NITAG challenges are not unique to LAC. NITAGs have outlined a short-term prioritized action plan which is critical to enhancing NITAG value and importance in countries. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.